Module

State-of-the-Art Management of Mantle Cell Lymphoma

Source: Promising Directions in Myeloma and Lymphoproliferative Disorders: Approaching Resistance, Retreatment, and Maintenance Through Novel Clinical Pathways

State-of-the-Art Management of Mantle Cell Lymphoma


Faculty:

  • Andre Goy, MD, MPH

CME CREDIT INFORMATION

Release Date: 04/22/08

Expiration Date: 04/21/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss approaches to the treatment of patients with relapsed or refractory mantle cell lymphoma that take into account variables such as prior treatment and response
  • Describe the etiology and biology of mantle cell lymphoma
  • Cite novel biologic therapies in clinical testing for patients with mantle cell lymphoma
  • Review the molecular pathways being targeted with emerging novel therapies
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grants provided by:

Educational grants support only the CME-certified components of this program.